{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T01:22:09Z","timestamp":1795051329461,"version":"4.10.2"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[2004,1,6]]},"abstract":"<jats:p>\n            <jats:bold>\n              <jats:italic>Background\u2014<\/jats:italic>\n            <\/jats:bold>\n            Cases of QT prolongation, torsades de pointes, and sudden death have been reported with arsenic trioxide (As\n            <jats:sub>2<\/jats:sub>\n            O\n            <jats:sub>3<\/jats:sub>\n            ), a highly effective agent for acute promyelocytic leukemia. In this study, we evaluated the effects of As\n            <jats:sub>2<\/jats:sub>\n            O\n            <jats:sub>3<\/jats:sub>\n            on repolarizing cardiac ion currents.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>Methods and Results\u2014<\/jats:italic>\n            <\/jats:bold>\n            In HERG- or KCNQ1+KCNE1-transfected CHO cells (n=32; total), As\n            <jats:sub>2<\/jats:sub>\n            O\n            <jats:sub>3<\/jats:sub>\n            caused concentration-dependent block of both\n            <jats:italic>I<\/jats:italic>\n            <jats:sub>Kr<\/jats:sub>\n            and\n            <jats:italic>I<\/jats:italic>\n            <jats:sub>Ks<\/jats:sub>\n            , with an IC\n            <jats:sub>50<\/jats:sub>\n            for tail current block of 0.14\u00b10.01 \u03bcmol\/L for\n            <jats:italic>I<\/jats:italic>\n            <jats:sub>Kr<\/jats:sub>\n            and 1.13\u00b10.06 \u03bcmol\/L for\n            <jats:italic>I<\/jats:italic>\n            <jats:sub>Ks<\/jats:sub>\n            . In contrast to other QT-prolonging drugs, As\n            <jats:sub>2<\/jats:sub>\n            O\n            <jats:sub>3<\/jats:sub>\n            also activated a time-independent current that additional experiments identified as\n            <jats:italic>I<\/jats:italic>\n            <jats:sub>K-ATP<\/jats:sub>\n            .\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>Conclusions\u2014<\/jats:italic>\n            <\/jats:bold>\n            As\n            <jats:sub>2<\/jats:sub>\n            O\n            <jats:sub>3<\/jats:sub>\n            blocks both\n            <jats:italic>I<\/jats:italic>\n            <jats:sub>Kr<\/jats:sub>\n            and\n            <jats:italic>I<\/jats:italic>\n            <jats:sub>Ks<\/jats:sub>\n            at clinically relevant concentrations. On the other hand, it also activates\n            <jats:italic>I<\/jats:italic>\n            <jats:sub>K-ATP<\/jats:sub>\n            , which maintains normal repolarization. We infer that variability in the extent of QT interval prolongation and onset of ventricular arrhythmias during arsenic therapy represents competing effects to block and activate multiple repolarizing potassium currents.\n          <\/jats:p>","DOI":"10.1161\/01.cir.0000109484.00668.ce","type":"journal-article","created":{"date-parts":[[2003,12,23]],"date-time":"2003-12-23T01:24:35Z","timestamp":1072142675000},"page":"26-29","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":89,"title":["Unusual Effects of a QT-Prolonging Drug, Arsenic Trioxide, on Cardiac Potassium Currents"],"prefix":"10.1161","volume":"109","author":[{"given":"Benoit","family":"Drolet","sequence":"first","affiliation":[{"name":"From the Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, Tenn."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantale","family":"Simard","sequence":"additional","affiliation":[{"name":"From the Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, Tenn."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan M.","family":"Roden","sequence":"additional","affiliation":[{"name":"From the Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, Tenn."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","first-page":"29","volume":"6","year":"2001","journal-title":"The Oncologist"},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.9.3354"},{"key":"e_1_3_2_3_2","first-page":"58","volume":"17","year":"1996","journal-title":"Chin J Hematol"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.18.3852"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811053391901"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-133-11-200012050-00012"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.009"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.5.1514"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-02-0598"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-008X(03)00127-3"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-200111000-00010"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112209200"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000082708.86266.b8"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-199508000-00012"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8167.1998.tb00889.x"},{"key":"e_1_3_2_16_2","first-page":"148","volume":"283","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","unstructured":"Terzic  A Vivaudou  M.  Molecular pharmacology of ATP-sensitive K + channels:  how and why? In:   Archer SL Rusch NJ eds.   Potassium Channels in Cardiovascular Biology.  New York:  Kluwer Academic\/Plenum Publishers;  2001:  257\u2013277.","DOI":"10.1007\/978-1-4615-1303-2_15"},{"key":"e_1_3_2_18_2","unstructured":"Klaassen  CD.  Heavy metals and heavy-metal antagonists. In:   Hardman JG Limbird LE Goodman Gilman A eds.   Goodman & Gilman\u2019s The Pharmacological Basis of Therapeutics.  New York:  McGraw-Hill;  2001:  1851\u20131875."}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/01.CIR.0000109484.00668.CE","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T18:37:07Z","timestamp":1715020627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.CIR.0000109484.00668.CE"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1,6]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1,6]]}},"alternative-id":["10.1161\/01.CIR.0000109484.00668.CE"],"URL":"https:\/\/doi.org\/10.1161\/01.cir.0000109484.00668.ce","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,1,6]]},"assertion":[{"value":"2003-12-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}